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Abstract
Background In line with current guideline recommenda-
tions, patients at high cardiovascular risk are usually trea-
ted with statins for secondary as well as for primary
prevention. While many studies investigated treatment goal
achievement with regards to low-density lipoprotein
(LDL-C) and total cholesterol (TC) there is paucity of data
regarding high density lipoprotein (HDL-C), and/or tri-
glycerides (TG).
Setting Prospective, cross-sectional study (Dyslipidemia
International Survey, DYSIS) with data provided by 748
ofﬁce-based physicians throughout Germany.
Methods Consecutive patients were eligible for partici-
pation, if they were at least 45 years old, currently treated
with a statin and had had a documented lipid proﬁle
(at least 1 parameter) within the last 6 months. Besides
descriptive analyses, logistic regression was performed
with backward selection to assess predictors for lipid
abnormalities (non-attainment of goals for TC, LDL-C,
low HDL-C or elevated TG) classiﬁed according to current
European Society of Cardiology guidelines.
Results The 4,282 documented patients (98.6% Cauca-
sian, 56.4% male; 86.6% at high cardiovascular risk) were
predominantly treated with simvastatin (83.9%), pravasta-
tin (7.7%) or atorvastatin (3.9%), usually with doses
equivalent to simvastatin 20–40 mg daily. Non-statins
were used in at most 12% of patients. No lipid abnormal-
ities were found in 21.0% of patients, one abnormality in
38.5%, two in 31.9%, and all three in 8.5%. LDL-C goals
were not attained in 58.1%, elevated TC was found in
66.6%, low HDL-C in 22.7%, and elevated TG in 47.3%.
In the multivariate logistic regression model, non-attain-
ment of LDL-C levels was predicted by hypertension (odds
ratio, OR 1.4), current smoking (OR 1.3), sedentary life-
style (OR 1.3), and female gender (OR 1.3). On the other
hand, a reduced risk for missing LDL-C targets was noted
in the presence of ischemic heart disease (OR 0.6), diabetes
(0.5), higher statin doses, ezetimibe treatment, or specialist
care, respectively.
Conclusion A substantial proportion of statin-treated
patients not only missed targets for LDL-C, but also did not
attain the normal levels for HDL-C and/or TG. There is a
large disconnect between high prevalence of HDL and/or
TG disorders, with or without elevated LDL-C, and utili-
zation of therapies targeting these lipids. Particularly in
high-risk patients, additional efforts should be made to
improve their lipid proﬁle.
Keywords Dyslipidemia  High density lipoprotein
cholesterol  Statins  Treatment targets  Primary care
A. K. Gitt  C. Ju ¨nger
Institut fu ¨r Herzinfarktforschung Ludwigshafen an der
Universita ¨t Heidelberg, Ludwigshafen, Germany
A. K. Gitt
Kardiologie, Medizinische Klinik B, Herzzentrum
Ludwigshafen, Ludwigshafen, Germany
W. Smolka  K. Bestehorn (&)
Medical Department, MSD Sharp & Dohme GmbH,
85540 Haar, Germany
e-mail: kurt.bestehorn@msd.de
K. Bestehorn
Institute for Clinical Pharmacology, Technical University,
Dresden, Germany
123
Clin Res Cardiol (2010) 99:723–733
DOI 10.1007/s00392-010-0177-zIntroduction
Substantial gains in cardiovascular disease (CVD) pre-
vention have been made in the recent years in the Western
industrialised countries [1, 2], owing in particular to the
earlier identiﬁcation of patients at high risk and the man-
agement of their modiﬁable risk factors [3]. However,
these improvements are now challenged by the impact of
the global epidemics of metabolic syndrome, obesity, and
type 2 diabetes mellitus [4, 5]. A high proportion of
patients with these conditions have complex lipid abnor-
malities (dyslipidemia), which are not restricted to elevated
low-density cholesterol (LDL-C) or total cholesterol (TC)
levels, but often comprise reduced levels of high density
lipoprotein cholesterol (HDL-C) and/or elevated triglycer-
ides (TG) [6, 7]. The central role of dyslipidemia as a major
contributor to CVD risk was highlighted by the global
case–control INTERHEART study, in which the condition
was responsible for 54% of population-attributable risk for
myocardial infarction [8]. Further, dyslipidemia is associ-
ated with substantial costs for the health care system, for
example due to productivity loss [9].
There are stringent dyslipidemia treatment goals for
patientswithtype2diabetesorCVD;however,guidelinesin
high-risksubjectswithoutdiabetesorCVDarelessstrictand
are based primarily on LDL-C, with non-HDL concentra-
tions as secondary consideration in some subjects [10].
Extensive evidence from large-scale prospective studies has
demonstrated that LDL-C lowering therapies (primarily
statins)substantiallyreduceriskofCVDeventsinpatientsat
high risk of any type of major vascular event: for every
1 mmol/L (39 mg/dL) decrease in LDL-C, the risk of major
cardiovascular events is decreased by 21% [11].
However, even in patients with optimal LDL-C reduc-
tion, a high residual risk of atherothrombotic events
remains [12]. Further substantial risk reduction is likely to
require alternative or supplementary approaches, focusing
on HDL-C [13] or TG, too. According to the National
Cholesterol Education program (NCEP ATP III), thera-
peutic intervention targeting low HDL-C and high TG
should be initiated in high-risk individuals with these
additional lipid abnormalities [14].
Various cross-sectional studies have assessed the prev-
alence of lipid abnormalities in different populations at risk
[15–20]. However, these studies have substantial differ-
ences in methodologies and deﬁnitions of target groups.
Little recent information is available on the prevalence of
persistent dyslipidemia in patients treated with statins in a
real-life setting, and how their lipid proﬁle is related to
patient characteristics. The present study aimed (1) to
estimate the prevalence of persistent dyslipidemia (missed
goals for LDL-C, TC, low HDL-C, elevated TG) in statin-
treated patients; (2) to describe the risk factor proﬁles and
lipid-lowering treatment of patients by index disease
(coronary artery disease; diabetes mellitus) or elevated
risk; and (3) to investigate predictors for non-achievement
of various recommended lipid values.
Methods
Study design
The Dyslipidemia International Survey (DYSIS) is string of
epidemiological studies. The German part as reported here
was conducted in 748 centres throughout Germany, with the
study period being 1April 2008–30 May2008. Itwas purely
observational, as only available data were documented, and
treatment or assessment of patients was not changed by
participation in the study. The Ethics Committee of the
Bavarian Physician Chamber in Munich, Germany,
approved the protocol. All patients provided written
informed consent prior to participation. Data protection was
closely observed. A randomly assigned 1% sample of cen-
tres underwent audits for data source veriﬁcation.
Physicians
Ofﬁce-based physicians (GP/family practitioner, internist,
cardiologist, endocrinologist) were eligible for participa-
tion. The protocol stipulated that the selection of physi-
cians in the study was to be determined to ensure
homogeneity and a good representation of the study patient
population at the country level. The site selection method
was performed at the country level and took the following
criteria into account: (a) physician proﬁles: GPs/family
practitioners, internists, cardiologists, endocrinologists; (b)
location: administrative region within the country; (c)
medical practices: ofﬁce based, hospital based. From a list
of physicians meeting these distribution criteria, the ﬁrst
748 respondents to the invitation from the sponsor were
nominated as investigators. Centres were balanced
according to the above criteria and there was no obvious
selection bias. Participating physicians documented other
characteristics related to their practice (age, gender, prac-
tice size, etc.).
They agreed to enrol six consecutive patients fulﬁlling
the inclusion criteria. The specialty of participating phy-
sicians was recorded. The physicians received reimburse-
ment of € 40 per patient enrolled.
Patients and schedule
Consecutive outpatients were eligible for participation, if
they were at least 45 years old, currently treated with a
statin and had had a documented lipid proﬁle (at least 1
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123parameter) within the last 6 months. All data requested in
the case report form were collected from the patient clin-
ical examination or from the review of the patient chart.
Data were recorded at one single visit. In view of the
observational character of the study, no safety assessments
were part of the protocol.
Documented parameters
Physicians were requested to document the following
parameters at one visit: demographics of the patient (gen-
der, age, race), body weight, height, waist circumference.
In terms of lipid parameters, the latest lipid test available
within the last 6 months, obtained while the patient had
been on statin therapy for at least 3 months was used. All
lipid parameters available from that blood test were col-
lected (TC, LDL-C, HDL-C, TG), if available. Cardio-
vascular risk factors were documented.
Diabetes mellitus was deﬁned as physician diagnosis,
serum glucose C126 mg/dL (C7 mmol/L) in latest avail-
able lab test or patient currently on antidiabetic or insulin
therapy. Elevated fasting plasma glucose was deﬁned as
serum glucose C100 mg/dL (C5.55 mmol/L) in latest
available lab test. Metabolic syndrome was recorded
according to the deﬁnition of the International Diabetes
Federation [21]. Waist circumference was measured in
standing position at the midpoint between the iliac crest
and the costal margin in the mid-axillary line (cutoffs
C102 cm for men, C88 cm for women). Hypertension was
deﬁned as treatment of previously diagnosed hypertension
or blood pressure values C140/90 mmHg. Current smoking
was recorded if the patient was currently smoking or
stopped smoking less than a year ago; past smoking if the
patient has stopped smoking over a year ago. First grade
family history of premature CV disease was considered if a
ﬁrst-degree relative (parents, brothers or sisters) suffered
from any early manifestation of atherosclerotic cardiovas-
cular disease (\55 years in men and\65 years in women).
Sedentary lifestyle was determined if the patient did not
conduct usual physical activity (i.e. a minimum of walking
20–30 min on 3–4 days a week or equivalent). Alcohol
consumption was reported as the average number of drinks
per week.
Manifestations of cardio- and cerebro-vascular diseases
were documented: coronary artery disease (CAD), prior
myocardial infarction or coronary revascularization [per-
cutaneous coronary intervention (PCI) and/or coronary
artery bypass surgery (CABG)]; cerebrovascular disease
(prior stroke or transient ischemic attack), peripheral arte-
rial disease (PAD), intermittent claudication or peripheral
artery revascularization; symptomatic chronic heart failure
according to New York Heart Association Heart Failure
Classiﬁcation Class (NYHA) II–IV.
Medication
The documentation of chronic medication focused on statin
therapy. The indication for statin treatment was noted (e.g.
hypercholesterolemia), as well as the name and daily dose
of the statin taken by the patient at the time of visit as well
as at the time of the latest available lipid test. Further, other
lipid-modifying therapies (cholesterol absorption inhibitor
[CAI], bile acid sequestrants, ﬁbrate, nicotinic acid), at visit
and before latest lipid test were documented. Further, an-
tihypertensives, antidiabetics, antiplatelets were recorded.
Treatment goals
LDL-C treatment goals were \3 mmol/L in patients with
SCORE risk \5%, and \2.5 mmol/L) in patients with
SCORE risk C5%, diabetes, and/or CVD. TC treatment
goals were\5 mmol/L in patients with SCORE risk\5%,
and \4.5 mmol/L in patients with SCORE risk C5%,
diabetes mellitus, and/or CVD.
Data entry and analysis
Physicians could decide to enter the data on paper/pencil
case record forms (CRF) or on electronic CRFs via the
internet.
Since the objectives of this study were descriptive in
nature, no formal hypothesis testing was done. Exploratory
prespeciﬁed analyses were done for subgroups or regions
within each country. No correction for multiplicity was
made. Descriptive statistics [mean, standard deviation,
range, percentiles, proportions, 95% conﬁdence intervals
(CI), etc.] were calculated for prespeciﬁed subgroups
deﬁned by lipid abnormalities, age, gender, CV risk factors
and levels, comorbidities, treatment patterns and regions.
Patient characteristics of the entire population and of
deﬁned subgroups were described using descriptive statis-
tics [mean with standard deviation (SD), median, inter-
quartile range]. Subgroups were deﬁned pre-hoc: patients
with CAD alone; patients with diabetes mellitus alone;
patients without diabetes or CAD but with 10-year event
risk C5% according to the ESC SCORE [22]; patients
without diabetes or CAD but with 10-year event risk\5%
according to the ESC SCORE. Post hoc analyses were
performed to investigate differences in patient character-
istics and treatment between these subgroups, using chi-
square tests.
A proportional odds model was used to evaluate
potential determinants of lipid control. Target levels and
other deﬁnitions for lipid parameters (LDL-C, TC, HDL-C,
TG) were based on the ESC guidelines [23].
Bivariateassociationsweretestedbyplacingeachvariable
into a separate proportional odds model. For categorical
Clin Res Cardiol (2010) 99:723–733 725
123variables, referent variables were created. The proportional
odds assumption was not violated for any variables on
bivariate analysis at a p value B0.05. Models contained the
following variables: age, gender, ﬁrst-degree relative with a
history of premature CVD, current smoker, sedentary life-
style, alcohol consumption[2 units/week, BMI C30 kg/m
2
(obesity), waist circumference[102 cm in men/[88 cm in
women, hypertension, diabetes mellitus, ischemic heart dis-
ease, cerebrovascular disease, heart failure, peripheral artery
disease, BP C140/90 mmHg (systolic/diastolic), 20–40 ver-
sus 10 mg/day simvastatin equivalent, C80 versus 10 mg/
day simvastatin equivalent, ezetimibe, physician’s specialty.
To obtain equivalents for statin potency, all statins were
categorised in ﬁve potencies (see legend to Fig. 1), using the
‘‘rule of 5 in lipid-lowering by statin drugs’’ by Roberts [24],
and the assumption of Knopp [25] that in general, a doubling
ofthedoseabovetheminimaleffectivedosedecreasesserum
LDL-C concentrations by an additional 6%. Backward
elimination (a = 0.05) was performed. Statistical signiﬁ-
cance was accepted at the two-sided 0.05 level, and all con-
ﬁdence intervals were computed at the 95% level. Statistical
analyseswereperformedwithSASversion9.1(SASInstitute
Inc., Cary, NC, USA, 1999).
Results
Oftheparticipating748physicians,79.9%wereprimarycare/
familyphysicians, and 20.1% werespecialists (9% internists,
7% cardiologists, 4% endocrinologists/diabetologists).
Patient characteristics and ESC risk level
Patient characteristics are summarized in Table 1. The
documented 4,282 patients were almost exclusively
Caucasian (98.6%), predominantly elderly (67 ±
9.7 years), with a slight dominance of males (56.6%). As
expected, risk factors were prevalent, in particular arterial
hypertension (85.7%), metabolic syndrome (70.8%), dia-
betes (45.7%) and overweight or obesity (35.4%). In the
descriptive comparison, women were on average older, and
more often were assigned the diagnosis metabolic
syndrome.
When applying the ESC SCORE C5%, the diagnoses
CAD or diabetes for categorisation of high risk, the great
majority of patients (89.6%; men more often than women)
fell into this group.
Treatment
The great majority of patients were on chronic simvastatin
treatment (83.9%). Other statins were less frequently
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Table 1 Patient characteristics
All patients
(N = 4,260)
Age (years), mean ± SD
a 67.1 ± 9.7
Caucasian (%) 98.6
Gender male (%) 56.6
Family history of premature CAD (%) 35.1
Current smokers (%) 13.6
Hypertension (%) 85.7
Systolic BP (mmHg), mean ± SD
b 131.0 ± 14.5
Diastolic BP (mmHg), mean ± SD
b 79.6 ± 8.3
Waist circumference (cm), mean ± SD
d 102.0 ± 14.1
BMI (kg/m
2), mean ± SD 28.9 ± 5.1
BMI[30 kg/m
2 (%) 35.4
Metabolic syndrome (IDF deﬁnition)
c 70.8
ESC risk level
High risk (CVD, diabetes and/or
SCORE risk C5%) (%)
i
89.6
CVD (%) 59.1
Diabetes mellitus (%) 45.7
SCORE risk C5% (%) without CVD and diabetes
i 11.4
SCORE risk\5% (%) without CVD and diabetes
i 10.4
LDL-C (mmol/L), mean ± SD
e 2.9 ± 0.9
HDL-C (mmol/L), mean ± SD
f 1.4 ± 0.4
TG (mmol/L), median, IQR
g 1.6 (1.2–2.3)
TC (mmol/L), mean ± SD
h 5.1 ± 1.2
CAD coronary heart disease, BP blood pressure, BMI body mass
index, CVD cardiovascular disease, DM diabetes mellitus,
IDF International Diabetes Federation
a Data on 4,228 patients were available,
b data on 4,257 patients were
available,
c data on 3,854 patients were available,
d data on 4,239
patients were available,
e data on 3,903 patients were available,
f data
on 3,699 patients were available,
g data on 3,735 patients were
available,
h data on 4,180 patients were available,
i data on 4,222
patients were available
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123prescribed: pravastatin in 7.6%, atorvastatin in 3.9%, ﬂu-
vastatin in 3.0%, and lovastatin in 1.5%.
The majority of patients received statin dose potency in
the intermediate range (equivalent to simvastatin 20 or
40 mg/day, Fig. 1).
With regards to other lipid-lowering treatment, ezetim-
ibe was reported in 13.2% (ﬁxed combination with sim-
vastatin in 7.0%, in free combination with any other statin
in 6.2%), ﬁbrates in 11.2%, nicotinic acid in 0.7%, and bile
acid sequestrants in 0.5%.
Lipid abnormalities
Table 2 summarizes lipid abnormalities, deﬁned by various
categories. No lipid abnormalities were found in 21.1% of
statin-treated patients, isolated LDL-C not at goal was
found in 25.0% of patients, LDL-C not at goal ? low
HDL-C and/or elevated TGs in 33.6% of patients, LDL-C
at goal ? low HDL-C and/or elevated TGs were found in
20.3% of patients. Corresponding numbers in patients with
diabetes mellitus and in patients with coronary heart dis-
ease without concomitant diabetes mellitus were: no lipid
abnormalities in 19.8/28.2% of patients, isolated LDL-C
not at goal was found in 17.2/27.8% of patients, LDL-C not
at goal and/or low HDL-C and/or elevated TGs in 36.2/
26.9% of patients, LDL-C at goal and/or low HDL-C and/
or elevated TGs were found in 26.9/17.0% of patients
(Fig. 2a, b).
Despite treatment, two-thirds of patients (66.2%) did not
attain TC targets, and more than half missed LDL-C targets
(58.6%). Elevated TG values were documented in about
half of the patients (46.9%). When regarding risk sub-
groups, patients with CVD alone had better control rates
compared to those with diabetes (without CVD), or ESC
SCORE C5%.
Predictors for lipid abnormalities
In the multivariate logistic regression models, a number of
variables were identiﬁed which independently were asso-
ciated with lipid abnormalities (Table 3). With regards to
non-achievement of LDL-C levels, presence of elevated
blood pressure (C140 mmHg) was associated with a 37%
risk increase (compared to individuals without this condi-
tion), current smoking with 32%, sedentary lifestyle with
32%, and female gender with a 26% risk increase. On the
other hand, presence of ischemic heart disease decreased
risk by 44%, presence of diabetes by 37%, and of obesity
by 18%. Further, treatment with higher statin doses or with
ezetimibe was associated with good control, as was spe-
cialist care.
Discussion
This large-scale cross-sectional study indicated that despite
statin treatment the lipid proﬁle of only every ﬁfth patient
reached the target values as recommended by current
practice guidelines, while the large majority of high-risk
patients still had one or more manifestations of
dyslipidemia.
In the recent years, a large number of studies and sur-
veys have investigated lipid goal attainment in the general
population or in the primary care setting. However, they
had a clear-cut focus on LDL-C (less frequently also on
TC), most recently the Kaiser Permante NW (USA) [26],
the 4E Registry (Germany) [27], NHANES III (USA) [28],
or the Oslo Registry (Norway) [29]. One of the few more
comprehensive analyses was based on the US NHANES,
where of the total sample (n = 1,111) with dyslipidemia,
85% remained uncontrolled for LDL-C, HDL-C, and or
Table 2 Lipid abnormalities (%) according to ESC guidelines in all patients
All patients
(N = 4,222)
High risk
(N = 3,783)
a
CVD
(N = 2,515)
Diabetes without
CVD (N = 785)
SCORE risk C5%
(N = 483)
SCORE risk\5%
(N = 439)
TC not at goal (%)
b 66.6 65.7 59.6 71.3 88.4 73.8
LDL-C not at goal (%)
c 58.1 58.1 52.7 61.3 83.3 58.7
Low HDL-C [\1.0 (men)/1.2
(women) mmol/L] (%)
d
22.7 23.1 24.8 24.0 12.9 18.7
Elevated TG ([1.7 mmol/L) (%)
e 47.3 47.5 45.9 54.3 44.6 45.2
a High risk = CVD, diabetes, and/or SCORE risk C5%
b TC C5 mmol/L in patients with SCORE risk\5%, and TC C4.5 mmol/L in patients with SCORE risk C5%, diabetes, and/or CVD. Data on
4,175 patients were available
c LDL C3 mmol/L in patients with SCORE risk\5%, and LDL C2.5 mmol/L) in patients with SCORE risk C5%, diabetes, and/or CVD. Data
3,887 patients were available
d Data on 3,685 patients were available
e Data on 3,727 patients were available
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123TG; 36% had more than 2 lipid disorders, while 42% had
HDL-C and/or TG disorders with or without elevated
LDL-C [30].
Most of the prior studies on lipid abnormalities focused
on LDL-C only based on the recommendations of NCEP
ATP III [31, 32]. Our study, however, took a broader
perspective, as it also considered HDL-C and TG besides
LDL-C, all of which are major contributors to cardiovas-
cular risk.
Our data indicated that overlap of lipid abnormalities
was frequent, as in the total cohort 41.2% of patients had
two or three lipid abnormalities at the same time. One out
of 12 patients (8.3%) presented with abnormalities of all
three lipid values, LDL-C, HDL-C and TG, which may
pose substantial therapeutic challenges to the physician.
Furthermore, additional risk factors and comorbidities such
as diabetes or CAD added to the total risk of the patients.
Patients with already manifest cardiovascular disease
more often reached the recommended target values for
LDL-C, TC and TG parameters as compared to patients
with diabetes but without manifest CVD. Our ﬁndings
conﬁrm previous reports according to which despite their
known risk, patients with diabetes are less often treated
according to current guidelines for lipid-lowering therapy
[33, 34].
The prevalence of low HDL-C and elevated levels of TG
was high in DYSIS. A strong reciprocal association
between HDL-C plasma concentrations and incidental
CAD events was described in different trials [35–37]. Also
the PROCAM cohort conﬁrmed this association even after
adjustment for other cardiovascular risk factors [38, 39].
Elevated triglycerides were predictors of CAD in univari-
ate analyses in many studies, but failed to predict adverse
events in multivariate analyses [38]. This may be due to
large inter- as well as intra-individual biological and lab-
oratory variability [40], as well as to the high prevalence of
additional abnormalities in HDL-C and LDL-C [10].
Nevertheless, according to the recent consensus conference
Fig. 2 a Lipid proﬁle in all
patients. b Lipid proﬁle in
diabetic patients and patients
with coronary heart disease but
no concomitant diabetes
mellitus
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123report on lipoprotein management in patients with cardio-
metabolic risk, treatments inducing HDL-C increase and
TG lowering are class II indications [10].
According to the proportional odds model which was
used to evaluate potential determinants of lipid control,
numerous variables were associated with one or more
persistent lipid abnormalities. Risk factors such as smok-
ing, sedentary lifestyle, obesity/increased waist circumfer-
ence, and hypertension were associated with poor control
of at least three of the four assessed lipid abnormalities.
Although patients with known diabetes were more likely to
reach target LDL-C levels as compared to patients without
diabetes and without CAD, still nearly two-thirds of the
diabetic patients were not at goal for LDL-C in clinical
practice. Additionally, known diabetes also signiﬁcantly
was associated with poor control of HDL-C and TG. These
disparate results are not unusual for statin-treated patients
who have substantially lowered LDL-C levels, but often
abnormal HDL-C or TG values [41, 42]. In DYSIS, spe-
cialist care was associated with better LDL-C and TG
control, mainly due to the use of higher doses of statins or
the add-on of ezetimibe.
Intermediate statin doses equivalent to 20–40 mg/day
simvastatin were frequently used in our study. As expected,
these doses compared to low doses equivalent to 10 mg/
day simvastatin were associated with an increased chance
to reach recommended LDL-goals. In the recent 2L Reg-
istry in 6,711 patients with manifest CAD and/or CAD
equivalent the mean simvastatin dose was 25 mg/day at
entry and 31 mg/day at discharge [43]. Rates of ezetimibe
as combined with statins in our study were 13% as in the
2L Registry at the baseline visit [43]. Thus, the prescription
rates for ezetimibe were increased compared to those
reported from statutory health insurance in 2008, the latest
available data (of all daily deﬁned doses for lipid-lowering
medications: statins 90.3%, ezetimibe 6.5%, ﬁbrates 2.9%,
other 0.3%) [44].
We documented a large disconnect between high prev-
alence of persistent HDL and/or TG disorders independent
of the LDL-C levels reached under chronic statin treat-
ment. Similar ﬁndings were described by a recent
NHANES analysis, in which the rate of therapies targeting
these HDL-C or TG was below\12% [30].
Four previous studies assessed determinants for lipid
control in clinical practice, all focusing on LDL-C target
attainment. In an analysis of the Vascular Protection (VP)
and the Guidelines Oriented Approach to Lipid Lowering
(GOALL) registries, with 8,056 high-risk ambulatory
patients, factors signiﬁcantly associated with treatment
success were increasing age (OR 1.5, 95% CI 1.3–1.7),
diabetes mellitus (OR 1.4; 1.3–1.6), CAD (OR 1.3; 1.2–
1.5), prior PCI or CABG (OR 1.5; 1.3–1.7) and statin
therapy (OR 2.3; 2.0–2.5) [45]. Similar ﬁndings were
documented in the Lipid Treatment Assessment Project
(L-TAP) with 4,888 patients [46]. In a retrospective analysis
of 8,353 women at high cardiovascular risk in a large
managed-care database, predictors of optimal combined
lipid level attainment were treatment with lipid-lowering
medication (OR 3.6; 95% CI 3.1–4.2), higher age
([77 years, OR 1.4; 1.1–1.8), diabetes mellitus (OR 1.4;
1.1–1.6), CHD (OR 1.3; 1.03–1.5), and metabolic syn-
drome (OR 0.4; 0.3–0.5) [47]. Eventually, in the NCEP
Evaluation Project Utilizing Novel E-Technology (NEP-
TUNE II) in 4,885 patients with CHD, diabetes or other
CHD risk equivalents, factors associated with goal
achievement in the CHD and CHD risk equivalent group
were three or more major risk factors (OR 1.3; CI not
reported), increasing age (OR 1.7), hypertension (OR 1.2),
compliance with diet therapy (OR 1.2), and subspecialties
versus primary care (OR 1.8) [48].
The DYSIS study had several strengths and limitations.
DYSIS was an observational cross-sectional trial which
collected data in a uniform, prospective way in 748 prac-
tices across Germany. The collection of observational data
in community settings provides more realistic and repre-
sentative information about the characteristics and man-
agement of patients in real clinical practice as compared to
randomised clinical trials [49]. However, physicians will-
ing to participate in the survey may be already a selection
of physicians with particular interest and knowledge in the
ﬁeld of lipid-lowering therapy. It may be possible that
physicians less focused on lipid management are less likely
to adhere to stringent guidelines and treatment goals [50].
As noted in studies in other indications, it cannot be
excluded that the absence of data from individuals who
declined study participation could have affected the
ﬁndings.
Furthermore, logistic regression analysis can balance
only covariates that were assessed and used to construct the
model. Other variables, not assessed in the analysis, may be
valid predictors for (non-)achievement of lipid goals/nor-
mal levels as well. Finally, the present survey was cross-
sectional and did not describe possible temporal changes in
medication. However, the rate of adaptation of treatment
was rather low in clinical practice as documented by the
TROL Registry [51].
Conclusion
A majority of statin-treated patients in Germany were not
at lipid goals and/or had abnormal levels of HDL-C and
triglycerides. DYSIS demonstrates the gap between
guideline recommendations and clinical practice and the
need for a more intensive and comprehensive lipid man-
agement in this high-risk population. The focus in
730 Clin Res Cardiol (2010) 99:723–733
123secondary prevention should not be just treating hyper-
cholesteremia, but treating to recommended target values
to maximally reduce the risk for subsequent adverse car-
diovascular events.
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